Explore Our Impact
Annual Reports Financial Statements
Integrity is one of our fundamental values and a cornerstone of our relationship with our supporters. As a GuideStar Gold-status organization, we are committed to ensuring your donation funds the translation of our cancer-killing technology, Laser-Activated NanoTherapy (LANT), into humans—including the costs of FDA approval, large-animal studies, and human clinical trials. Our founder, Dr. Hadiyah-Nicole Green, has been nationally recognized for developing LANT, which completely eliminates human tumors in mice in just 15 days after a single 10-minute treatment, without any observed side effects. We are endeavoring to ensure this treatment is affordable for all by funding human clinical trials as a 501(c)(3) with the support of philanthropists, donors, partners, sponsors, and volunteers. All overhead has been covered by our founder’s personal contributions; 100% of all funds raised from our donors are dedicated to their intended purpose.
We invite you to review our annual reports, financial statements, and 990s to learn more about the Ora Lee Smith Cancer Research Foundation, our progress, and our values. With our FDA Breakthrough Device Designation — a recognition the FDA reserves for technologies that show exceptional promise — we are prepared to begin human trials in as little as 12 months of raising $10 million as a first step in a $100 million+ endeavor. We hope you will be inspired to join our journey, adopt us as your cancer charity of choice, and become a sustaining supporter. Donate today and directly determine how soon we launch human trials and begin saving cancer patients.
Our Mission & Legacy
The Ora Lee Smith Cancer Research Foundation was established by Dr. Hadiyah-Nicole Green in memory of her beloved aunt, Ora Lee Smith. Our mission is to revolutionize cancer treatment by developing groundbreaking, physics-inspired therapies that are effective, accessible, and affordable. Designed as a multi-cancer platform therapy with the potential to save millions of lives, this breakthrough has implications for a variety of solid tumor types — including skin, head and neck, brain, breast, prostate, colorectal, and a variety of inoperable, chemo-resistant cancers. We are endeavoring to ensure this treatment is affordable for all by funding human clinical trials as a 501(c)(3) with the support of philanthropists, donors, partners, sponsors, and volunteers. We are dedicated to reducing the physical and financial suffering of cancer patients worldwide and ensuring that life-saving innovations become financially accessible to all families, regardless of their economic circumstances. Through strategic partnerships, generous donations, and an unwavering commitment to excellence, we strive to bring our life-changing treatments from the laboratory to the patients who need them most. We are not just building a new therapy; we are honoring a legacy of love by ensuring that a cancer diagnosis no longer leads to physical or financial suffering.
Annual Report Overview
Key Achievements
Since its inception, the Foundation has moved from a viral vision to a federally recognized breakthrough: a treatment that completely eliminates human tumors in mice within 15 days after a single 10-minute treatment, with no observed side effects. Our revolutionary Laser-Activated NanoTherapy (LANT) has secured the prestigious FDA Breakthrough Device Designation and $2.3 million in research grants from the U.S. Department of Veterans Affairs—critical validations that place our technology at the forefront of modern medical science. Led by Dr. Hadiyah-Nicole Green—a recipient of the U.S. Presidential Lifetime Achievement Award and named one of USA Today’s 100 Women of the Century—we have built a global movement celebrated by icons like Beyoncé and featured in Forbes, ABC News, and The Talk. With our clinical trial protocols complete and the regulatory pathway clear, your support of our nonprofit initiative serves as the final bridge to human clinical trials, bringing us one step closer to making affordable and effective healthcare a reality for cancer patients everywhere.
Financial Highlights
donations towards Research
%
Volunteer Support
%
FOR-PROFIT INVESTMENTS ACCEPTED
%
Achievements and Honors
FDA Breakthrough Device Designation
Recognized for our innovative approach to cancer treatment, receiving the FDA’s prestigious designation.
Federal Funding and Infrastructure for First-in-Human Studies
Our founder was granted a $1.2 million Merit Scholar Award from the Department of Veterans Affairs as the Principal Investigator
Guidestar Platinum Seal of Transparency
Awarded for our commitment to transparency and accountability in all operations.
Annual Reports, Financial Statements, and 990s
CALENDAR YEAR
Each year of our journey, 2016-present, is available to provide transparency and context to our journey and commitment to ensuring our cancer-killing technology remains affordable and accessible.
ANNUAL REPORTS
Our Annual Reports, beginning with a letter from our founder, provide an overview of our highlights for the year and insights into our fundraising efforts and progress as we strive to reach the first $10M goal needed to begin human trials.
FINANCIAL STATEMENTS
Our financials reflect that, to date, our founder has covered all operational expenses; no other donations have been spent on overhead. 100% of donations are allocated to translating our cancer treatment into human trials.
990s
Our 990s are available for review, showcasing our dedication to transparency and accountability. Our fiscal year ends in December. Any delays can be attributed to COVID or extensions granted by the IRS.
2016
2016 Annual Report
2016 Financial Statements
2016 990s
2017
2017 Annual Report
2017 Financial Statements
2017 990s
2018
2018 Annual Report
2018 Financial Statements
2018 990s
2019
2019 Annual Report
2019 Financial Statements
2019 990s
2020
2020 Annual Report
2020 Financial Statements
2020 990s
2021
2021 Annual Report
2021 Financial Statements
2021 990s
2022
2022 Annual Report
2022 Financial Statements
2022 990s
2023
2023 Annual Report
2023 Financial Statements
2023 990s
2024
2024 Annual Report
2024 Financial Statements
2024 990s
Help Us, Save Lives.
Join Us in the Fight Against Cancer.
With our FDA Breakthrough Device Designation — a recognition the FDA reserves for technologies that show exceptional promise — we are prepared to begin human trials in as little as 12 months of raising $10 million as a first step in a $100 million+ endeavor. To date, we have raised approximately $4 million toward the first $10 million needed to begin human trials. Without your support, this could be a 20-year journey. Every $100 you give shortens that timeline by an hour. We are on the brink of a cancer revolution. Our breakthrough cancer treatment is funding-limited, not technology-limited. We hope you will join our journey, adopt us as your cancer charity of choice, and become a sustaining supporter. Your generous support is crucial to advancing our new cancer treatment from the laboratory to cancer patients. Every donation helps us move closer to a world where cancer is treated in 10 minutes without observable side effects. Together, we can move beyond hope and beyond research to start saving lives. Donate today and directly determine how soon we launch human trials and begin saving cancer patients.